Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression deals only with HDAC inhibitors from natural origins including bacteria, fungi, marine organisms and, notably, from diverse plant sources. This book is unique in the sense that it is the only book that discusses wholly and solely HDAC inhibitors of natural origin in the context of cancer chemotherapy. Another peculiar feature of this book is that it debates futuristic nanotechnology approaches for escalating the aqueous solubility, cancer cell uptake, bioavailability and other favourable pharmacological parameters, including the cytotoxicity of natural HDAC inhibitors against cancer cells.

The major features of this book encompass

• General compendium of HDAC inhibitors with deep emphasis on the toxicity issues of synthetic HDAC inhibitors
• Various groups of natural HDAC inhibitors, their representatives and premier sources
• Cyclic tetrapeptides of natural origin and their importance as cancer chemotherapeutic agents
• Hydroxamates and depsipeptides from natural sources and their promising role in cancer therapy
• Natural flavonoids, their HDAC inhibitory tendency and marvellous anticancer activity
• Non-flavonoid natural HDAC inhibitors and their pleasing cytotoxic effects towards cancer models
• Combined therapy involving natural flavonoids with other anticancer molecules for synergistic and additive benefits against cancer models
• Non-flavonoid HDAC inhibitors and conventional drugs in collaborative mode against aggressive malignancies
• Nanotechnology-based delivery of natural HDAC inhibitors for greater therapeutic efficacy over traditional combinatorial therapy

This book is highly beneficial to university professors and research scholars working on epigenetic therapeutics in general, and natural HDAC inhibitors in particular. This book is equally important to medical oncologists, biochemistry as well as pharmacy candidates and students of master's and undergraduate level with a desire to do a doctorate on HDACs, natural HDAC inhibitors, HDAC inhibitor (natural)-based combinatorial chemotherapy and delivery of these inhibitors selectively to tumour sites through revolutionary nanotechnological tactics.